Precision Medicine in Oncology® | Specialty

Soft Tissue Sarcoma: Unmet Needs

March 25th 2020

The Prognostic Value of Molecular Testing

March 25th 2020

Switching Therapy: Secondary Mutations and Resistance

March 25th 2020

Current Treatment Landscape of Soft Tissue Sarcoma

March 25th 2020

Diagnostic Testing Procedure for Soft Tissue Sarcoma

March 25th 2020

Dr. Goldman on the Use of Immunotherapy in Oncogene-Driven NSCLC

March 25th 2020

Jonathan W. Goldman, MD, health sciences clinical instructor, Department of Medicine, and Hematology/Oncology member, Jonsson Comprehensive Cancer Center Signal Transduction and Therapeutics Program, UCLA, discusses the use of immunotherapy in patients with oncogene-driven non–small cell lung cancer (NSCLC).

Dr. Husain on Ongoing Research Evaluating Plasma-Based Testing in Lung Cancer

March 25th 2020

Hatim Husain, MD, medical oncologist and associate professor of medicine, Moores Cancer Center, University of California, San Diego (UCSD), discusses ongoing research efforts evaluating plasma-based testing in lung cancer.

Dr. Iyer on Investigational FGFR Inhibitors in Metastatic Urothelial Carcinoma

March 20th 2020

Gopa Iyer, MD, discusses investigational FGFR inhibitors in metastatic urothelial carcinoma.

Dr. Otterson on Targetable Biomarkers in Lung Cancer

March 20th 2020

Gregory A. Otterson, MD, discusses targetable biomarkers in non–small cell lung cancer.

Dr. Sholl on Challenges With Using Tissue Biopsy for Biomarker Testing in Lung Cancer

March 19th 2020

Lynette M. Sholl, MD, discusses the challenges faced with the use of tissue biopsy to test for biomarkers in lung cancer.

Updated Guideline Moves Genetic Testing Beyond BRCA

March 13th 2020

Driven by advances in genetic testing methods and the discovery of actionable mutations beyond BRCA, an update to the National Comprehensive Cancer Network’s Guidelines for genetic testing in breast, ovarian, and pancreatic cancers encompasses a much broader range of genes that predict risk for disease occurrence.

Dr. Finn on Biomarkers of Response in HCC

March 12th 2020

Richard S. Finn, MD, discusses biomarkers of response to immunotherapy in hepatocellular carcinoma.

Dr. Iyer on Erdafitinib-Related Hyperphosphatemia in Metastatic Urothelial Cancer

March 12th 2020

Gopa Iyer, MD, discusses treatment-emergent hyperphosphatemia with erdafitinib in patients with metastatic urothelial cancer.

Dr. Dimou on Limitations of TMB as a Biomarker in Lung Cancer

March 11th 2020

Anastasios (Tassos) Dimou, MD, discusses the limitations of tumor mutational burden as a biomarker in lung cancer.

Dr. Polsky on the Unmet Need of Clinical Utility in Liquid Biopsy

March 10th 2020

David Polsky, MD, PhD, discusses the unmet need of clinical utility in liquid biopsy.

Neoadjuvant Cisplatin Not Superior to Standard Chemo in BRCA+ HER2-Negative Breast Cancer

March 10th 2020

Single-agent cisplatin did not lead to significantly higher pathologic complete response rates or improved residual cancer burden scores compared with doxorubicin plus cyclophosphamide in the neoadjuvant setting for patients with stage I to III HER2-negative breast cancer who harbor BRCA mutations.

The Applications of a Mixed Reality Laboratory

March 7th 2020

Andrea Sboner, MS, PhD, assistant professor of computational genomics in computational biomedicine and of pathology and laboratory medicine, Weill Cornell Medicine, discusses the applications of a mixed reality laboratory.

Larotrectinib Data Further Demonstrate Strong Efficacy in TRK+ Tumors

March 6th 2020

Larotrectinib continued to show strong tumor-agnostic efficacy in patients with TRK fusion–positive cancers, according to results from an integrated analysis of 3 clinical trials.

Dr. Husain on the Increased Use of and Challenges With Utilizing Liquid Biopsies

March 6th 2020

Hatim Husain, MD, discusses the increased use of and challenges with utilizing liquid biopsies.

Mayo Researchers: Change NCCN Criteria to Expand Genetic Testing in Breast Cancer

March 6th 2020

Researchers at the Mayo Clinic maintain that all women aged 65 or under with a breast cancer diagnosis should receive germline genetic testing to identify harmful mutations that increase their risk of developing secondary cancers.